1. Home
  2. RA vs ARVN Comparison

RA vs ARVN Comparison

Compare RA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Real Assets Income Fund Inc.

RA

Brookfield Real Assets Income Fund Inc.

HOLD

Current Price

$12.91

Market Cap

726.6M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$12.30

Market Cap

806.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RA
ARVN
Founded
2016
2015
Country
United States
United States
Employees
1260
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
726.6M
806.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
RA
ARVN
Price
$12.91
$12.30
Analyst Decision
Buy
Analyst Count
0
23
Target Price
N/A
$17.80
AVG Volume (30 Days)
280.8K
2.3M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
14.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$312,300,000.00
Revenue This Year
N/A
$11.06
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
93.86
52 Week Low
$11.89
$5.90
52 Week High
$17.32
$22.48

Technical Indicators

Market Signals
Indicator
RA
ARVN
Relative Strength Index (RSI) 38.74 55.73
Support Level $13.06 $12.47
Resistance Level $13.24 $13.56
Average True Range (ATR) 0.08 0.56
MACD -0.02 -0.08
Stochastic Oscillator 12.50 40.00

Price Performance

Historical Comparison
RA
ARVN

About RA Brookfield Real Assets Income Fund Inc.

Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Share on Social Networks: